It’s little secret that pharmaceutical giant Eli Lilly (NYSE:LLY) faces drug patent expirations on its top-selling drugs over the next few years. The question is the extent to which this is already reflected in the share price and whether the company can find a way to put billions in cash flow to good use and find a way out of its predicament.

Read the rest of this entry »